thalidomide has been researched along with Body Weight in 37 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial." | 9.11 | Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. ( Duncan, HD; Ellis, RD; Goggin, PM; Gordon, JN; Johns, T; Trebble, TM, 2005) |
| "Although thalidomide (Thal) was introduced successfully in the treatment of multiple myeloma (MM), the optimal Thal dosage and schedule are still controversial." | 9.10 | Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2002) |
| "Despite differences between real-world and trial patients, apremilast is safe and effective for the treatment of skin psoriasis in the daily practice." | 7.88 | Apremilast in psoriasis - a prospective real-world study. ( Herman, R; Monshi, B; Posch, C; Rappersberger, K; Richter, L; Sanlorenzo, M; Vujic, I, 2018) |
| "To evaluate the efficacy of thalidomide for treating troublesome cases of pediatric Crohn's disease (CD) with tuberculosis infection." | 7.85 | Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis. ( Hong, Y; Huang, Y; Leung, YK; Wang, L; Wu, J, 2017) |
| "The management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge in clinical practice." | 6.77 | Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. ( Cao, YZ; Li, X; Peng, LM; Shi, YM; Wen, HS; Yang, F; Zhang, CC, 2012) |
| "Lenalidomide is a potent immunomodulatory agent, with the ability to down-regulate pro-inflammatory cytokines and up-regulate anti-inflammatory cytokines." | 5.35 | Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E, 2009) |
| "Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial." | 5.11 | Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. ( Duncan, HD; Ellis, RD; Goggin, PM; Gordon, JN; Johns, T; Trebble, TM, 2005) |
| "Although thalidomide (Thal) was introduced successfully in the treatment of multiple myeloma (MM), the optimal Thal dosage and schedule are still controversial." | 5.10 | Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2002) |
| "Thalidomide therapy has been shown to cause increases in body weight in patients with HIV and tuberculosis infections." | 5.08 | The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. ( Diakun, J; Freedman, VH; Haslett, P; Hempstead, M; Kaplan, G; Seidman, C; Vasquez, D, 1997) |
| "Despite differences between real-world and trial patients, apremilast is safe and effective for the treatment of skin psoriasis in the daily practice." | 3.88 | Apremilast in psoriasis - a prospective real-world study. ( Herman, R; Monshi, B; Posch, C; Rappersberger, K; Richter, L; Sanlorenzo, M; Vujic, I, 2018) |
| "To evaluate the efficacy of thalidomide for treating troublesome cases of pediatric Crohn's disease (CD) with tuberculosis infection." | 3.85 | Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis. ( Hong, Y; Huang, Y; Leung, YK; Wang, L; Wu, J, 2017) |
| " To this end, we used Zucker diabetic fatty (ZDF) rats to examine the levels of TNFα, IL-1β, and NF-κB in the RVM during the development of neuropathic pain in type 2 diabetes, and evaluated the effects of intra-RVM microinjections of thalidomide on the levels of TNFα, IL-1β, and NF-κB in the RVM and mechanical allodynia and thermal hyperalgesia induced by type 2 diabetes." | 3.83 | Administrations of thalidomide into the rostral ventromedial medulla alleviates painful diabetic neuropathy in Zucker diabetic fatty rats. ( Gu, K; Guan, J; Liu, J; Ma, P; Song, T; Yang, G; Yang, Y; Zhang, Z; Zhao, J, 2016) |
| "The management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge in clinical practice." | 2.77 | Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. ( Cao, YZ; Li, X; Peng, LM; Shi, YM; Wen, HS; Yang, F; Zhang, CC, 2012) |
| "Thalidomide therapy was associated with mild to moderate rashes and fevers, but not peripheral neuropathy." | 2.69 | Thalidomide for the treatment of AIDS-associated wasting. ( Fessel, WJ; Fierer, DS; Haslett, PA; Kaplan, G; Kook, KA; Mulligan, K; Schambelan, M; Smith, LG; Stirling, D; Thomas, S, 2000) |
| "Isatuximab is used to treat multiple myeloma (MM), characterized by the excessive production of abnormal "myeloma proteins" (M-proteins) that may interact with therapeutic IgG mAb on the neonatal Fc receptor (FcRn)-mediated recycling pathway." | 1.56 | Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients. ( Brillac, C; Campana, F; El-Cheikh, R; Fau, JB; Koiwai, K; Mace, N; Nguyen, L; Semiond, D, 2020) |
| " This dosage form permits the prolonged drug release." | 1.39 | Evaluation of the effects of thalidomide-loaded biodegradable devices in solid Ehrlich tumor. ( Dantas Cassali, G; Ligorio Fialho, S; Maria de Souza, C; Pereira, BG; Silva-Cunha, A, 2013) |
| "Lenalidomide is a potent immunomodulatory agent, with the ability to down-regulate pro-inflammatory cytokines and up-regulate anti-inflammatory cytokines." | 1.35 | Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E, 2009) |
| "Thalidomide cannot inhibit VEGF mRNA expression of grafted H22 tumor in mouse." | 1.32 | [Effect of thalidomide on tumor growth in mouse hepatoma H22 model]. ( Lu, ZJ; Zhai, Y, 2003) |
| "Thalidomide had no adverse effects on mating and fertility in male and female rabbits dosed up to 500 and 100 mg/kg/day, respectively, for 14 days prior to mating." | 1.32 | Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits. ( Denny, KH; Hoberman, AM; Morseth, SL; Stirling, DI; Teo, SK; Thomas, SD, 2004) |
| "The present study determined effects of thalidomide on three successive generations of New Zealand White rabbits after oral dosing to F0 maternal rabbits during the later third of gestation (post major organogenesis) and lactation." | 1.32 | Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring. ( Denny, KH; Hoberman, AM; Morseth, S; Stirling, DI; Teo, SK; Thomas, SD, 2004) |
| "Thalidomide has no effect on tumor growth, but is also associated with increased VEGF and p53 expression." | 1.31 | Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. ( Bauer, AJ; Doniparthi, NK; Francis, GL; Patel, A; Ringel, MD; Saji, M; Terrell, R; Tuttle, RM, 2002) |
| "Thalidomide has been shown to have antiinflammatory and, more recently, immunomodulating properties, which are beneficial for the treatment of an ever-increasing list of immune related diseases." | 1.31 | Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. ( Brown, RD; Germolec, DR; Karrow, NA; McCay, JA; Munson, AE; Musgrove, DL; Pettit, DA; White, KL, 2000) |
| " The remaining 8 animals (2/sex/group; high-dose and control groups) were dosed for 53 weeks, euthanized, and necropsied at 58 weeks after a 5-week recovery period." | 1.31 | Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs. ( Brockman, MJ; Ehrhart, J; Evans, MG; Morgan, JM; Stirling, DI; Teo, SK; Thomas, SD, 2001) |
| " At the most, there is only a marginal loss of sensitivity in respect of detecting the lowest dosage at which effects may occur." | 1.27 | An indirect assessment of the Chernoff/Kavlock assay. ( Palmer, AK, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (35.14) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 14 (37.84) | 29.6817 |
| 2010's | 5 (13.51) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Fau, JB | 1 |
| El-Cheikh, R | 1 |
| Brillac, C | 1 |
| Koiwai, K | 1 |
| Mace, N | 1 |
| Campana, F | 1 |
| Semiond, D | 1 |
| Nguyen, L | 1 |
| Vujic, I | 1 |
| Herman, R | 1 |
| Sanlorenzo, M | 1 |
| Posch, C | 1 |
| Monshi, B | 1 |
| Rappersberger, K | 1 |
| Richter, L | 1 |
| Wang, L | 1 |
| Hong, Y | 1 |
| Wu, J | 1 |
| Leung, YK | 1 |
| Huang, Y | 1 |
| Wen, HS | 1 |
| Li, X | 1 |
| Cao, YZ | 1 |
| Zhang, CC | 1 |
| Yang, F | 1 |
| Shi, YM | 1 |
| Peng, LM | 1 |
| Yang, Y | 1 |
| Zhang, Z | 1 |
| Guan, J | 1 |
| Liu, J | 1 |
| Ma, P | 1 |
| Gu, K | 1 |
| Zhao, J | 1 |
| Yang, G | 1 |
| Song, T | 1 |
| Neymotin, A | 1 |
| Petri, S | 1 |
| Calingasan, NY | 1 |
| Wille, E | 1 |
| Schafer, P | 1 |
| Stewart, C | 1 |
| Hensley, K | 1 |
| Beal, MF | 1 |
| Kiaei, M | 1 |
| Pereira, BG | 1 |
| Ligorio Fialho, S | 1 |
| Maria de Souza, C | 1 |
| Dantas Cassali, G | 1 |
| Silva-Cunha, A | 1 |
| Rupnick, MA | 1 |
| Panigrahy, D | 1 |
| Zhang, CY | 1 |
| Dallabrida, SM | 1 |
| Lowell, BB | 1 |
| Langer, R | 1 |
| Folkman, MJ | 1 |
| Neben, K | 1 |
| Moehler, T | 1 |
| Benner, A | 1 |
| Kraemer, A | 1 |
| Egerer, G | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Bauer, AJ | 1 |
| Terrell, R | 1 |
| Doniparthi, NK | 1 |
| Patel, A | 1 |
| Tuttle, RM | 1 |
| Saji, M | 1 |
| Ringel, MD | 1 |
| Francis, GL | 1 |
| Zhai, Y | 1 |
| Lu, ZJ | 1 |
| Teo, SK | 4 |
| Denny, KH | 2 |
| Stirling, DI | 4 |
| Thomas, SD | 4 |
| Morseth, SL | 1 |
| Hoberman, AM | 2 |
| Morseth, S | 1 |
| Gordon, JN | 1 |
| Trebble, TM | 1 |
| Ellis, RD | 1 |
| Duncan, HD | 1 |
| Johns, T | 1 |
| Goggin, PM | 1 |
| Silvestrini, B | 1 |
| Barcellona, PS | 1 |
| Garau, A | 1 |
| Catanese, B | 1 |
| Cook, MJ | 1 |
| Moore, DF | 1 |
| Klausner, JD | 1 |
| Makonkawkeyoon, S | 1 |
| Akarasewi, P | 1 |
| Nakata, K | 1 |
| Kasinrerk, W | 1 |
| Corral, L | 1 |
| Dewar, RL | 1 |
| Lane, HC | 1 |
| Freedman, VH | 2 |
| Kaplan, G | 3 |
| Haslett, P | 1 |
| Hempstead, M | 1 |
| Seidman, C | 1 |
| Diakun, J | 1 |
| Vasquez, D | 1 |
| Karrow, NA | 1 |
| McCay, JA | 1 |
| Brown, RD | 1 |
| Musgrove, DL | 1 |
| Pettit, DA | 1 |
| Munson, AE | 1 |
| Germolec, DR | 1 |
| White, KL | 1 |
| Jakkula, M | 1 |
| Le Cras, TD | 1 |
| Gebb, S | 1 |
| Hirth, KP | 1 |
| Tuder, RM | 1 |
| Voelkel, NF | 1 |
| Abman, SH | 1 |
| Thomas, S | 1 |
| Fierer, DS | 1 |
| Mulligan, K | 1 |
| Haslett, PA | 1 |
| Fessel, WJ | 1 |
| Smith, LG | 1 |
| Kook, KA | 2 |
| Stirling, D | 1 |
| Schambelan, M | 1 |
| Evans, MG | 1 |
| Brockman, MJ | 1 |
| Ehrhart, J | 1 |
| Morgan, JM | 1 |
| Scheffler, MR | 1 |
| Tracewell, WG | 1 |
| Colburn, WA | 1 |
| Sofia, RD | 1 |
| Strasbaugh, JE | 1 |
| Banerjee, BN | 1 |
| Gershbein, LL | 2 |
| Palmer, AK | 1 |
| Mückter, H | 1 |
| Frankus, E | 1 |
| Moré, E | 1 |
| Kollmer, WE | 1 |
| Staemmler, M | 1 |
| Locker, D | 1 |
| Superstine, E | 1 |
| Sulman, FG | 1 |
| Fickentscher, K | 1 |
| Köhler, F | 1 |
| Keplinger, ML | 1 |
| Wright, PL | 1 |
| Plank, JB | 1 |
| Calandra, JC | 1 |
| Jonsson, BG | 2 |
| Rosenthale, ME | 1 |
| Datko, LJ | 1 |
| Kassarich, J | 1 |
| Schneider, F | 1 |
| Aeppli, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488] | Phase 2 | 52 participants (Actual) | Interventional | 2019-03-26 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [NCT00004276] | Phase 2 | 50 participants | Interventional | 1990-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for thalidomide and Body Weight
| Article | Year |
|---|---|
Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide.
Topics: Aged; Appetite Stimulants; Body Weight; Cachexia; Drug Therapy, Combination; Fatigue; Female; Hand S | 2012 |
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; beta 2-Microglobulin; Body Height; Body Weight; C-Reactive | 2002 |
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
Topics: Aged; Angiogenesis Inhibitors; Body Weight; Cachexia; Double-Blind Method; Female; Humans; Male; Nut | 2005 |
The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; HIV-1; Humans; Immuno | 1996 |
The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus.
Topics: Body Composition; Body Weight; Calorimetry; Cohort Studies; HIV Infections; Humans; Male; Nitrogen; | 1997 |
Thalidomide for the treatment of AIDS-associated wasting.
Topics: Adult; Anti-HIV Agents; Body Composition; Body Weight; CD4 Lymphocyte Count; Double-Blind Method; En | 2000 |
Thalidomide dose proportionality assessment following single doses to healthy subjects.
Topics: Adult; Area Under Curve; Body Weight; Female; Humans; Leprostatic Agents; Male; Middle Aged; Thalido | 2001 |
30 other studies available for thalidomide and Body Weight
| Article | Year |
|---|---|
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; An | 2020 |
Apremilast in psoriasis - a prospective real-world study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Body Weight; Diarrhea; Drug Substi | 2018 |
Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis.
Topics: Adolescent; Antitubercular Agents; Blood Sedimentation; Body Weight; C-Reactive Protein; Child; Chil | 2017 |
Administrations of thalidomide into the rostral ventromedial medulla alleviates painful diabetic neuropathy in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Body Weight; Cytokines; Diabetic Neuropathies; Hyperalgesia; Immunosuppressi | 2016 |
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Body Weight | 2009 |
Evaluation of the effects of thalidomide-loaded biodegradable devices in solid Ehrlich tumor.
Topics: Absorbable Implants; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Antineoplastic | 2013 |
Adipose tissue mass can be regulated through the vasculature.
Topics: Adipose Tissue; Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Biphenyl Comp | 2002 |
Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Body Weight; Carcinoma; Cell Division; End | 2002 |
[Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
Topics: Angiogenesis Inhibitors; Animals; Body Weight; Carcinoma, Hepatocellular; Disease Models, Animal; Fl | 2003 |
Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits.
Topics: Aborted Fetus; Abortion, Spontaneous; Animals; Body Weight; Cesarean Section; Embryonic and Fetal De | 2004 |
Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring.
Topics: Abnormalities, Drug-Induced; Abortifacient Agents; Animals; Animals, Newborn; Body Weight; Dose-Resp | 2004 |
Thalidomide slows wasting in some pancreatic cancers.
Topics: Body Weight; Humans; Pancreatic Neoplasms; Thalidomide; Wasting Syndrome | 2005 |
Toxicology of benzydamine.
Topics: Amines; Animals; Anti-Inflammatory Agents; Ataxia; Body Weight; Cats; Diet; Dogs; Female; Growth; Li | 1967 |
The effect of thalidomide on the developing rat foetus.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Female; Pregnancy; Pregnancy, Animal; Rats; Thali | 1967 |
Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice.
Topics: Animals; Body Weight; Cell Count; Female; Immunoglobulin M; Immunosuppressive Agents; Injections, In | 2000 |
Inhibition of angiogenesis decreases alveolarization in the developing rat lung.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Barium Sulfate; Body Weight; Cyclohexanes; Fatty | 2000 |
Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs.
Topics: Animals; Body Weight; Bone and Bones; Clinical Chemistry Tests; Color; Dogs; Eating; Electrocardiogr | 2001 |
Positive results reported for thalidomide in AIDS wasting.
Topics: Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Wasting Sy | 1997 |
Teratologic evaluation of synthetic delta 9-tetrahydrocannabinol in rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Dronabinol; Eating; Female; Fetal Viability; Gest | 1979 |
The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Azoxymethane; Body Weight; Carcinogens; Colon; Dimet | 1991 |
An indirect assessment of the Chernoff/Kavlock assay.
Topics: Animals; Body Weight; Eating; Female; Fetus; Growth; Hemodynamics; Lethal Dose 50; Pregnancy; Rats; | 1987 |
[Experimental studies with cyclic imides in dimethylbenzanthracene tumors of Sprague-Dawley rats].
Topics: Animals; Benz(a)Anthracenes; Body Weight; Female; Hypophysectomy; Imides; Mammary Neoplasms, Experim | 1967 |
The mechanism of the push and pull principle. 8. Endocrine effects of thalidomide and its analogues.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Animals; Body Weight; Depression, Chemical; Female; Fol | 1971 |
Teratogenicity and embryotoxicity of thalidomide and 3-aza-thalidomide in mice.
Topics: Abnormalities, Drug-Induced; Animals; Aza Compounds; Body Weight; Bone and Bones; Depression, Chemic | 1974 |
Teratologic studies with FD and C red no. 2 in rats and rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Autopsy; Body Weight; Cleft Palate; Coloring Agents; Female; F | 1974 |
Teratological studies on thalidomide in rats.
Topics: Abnormalities, Drug-Induced; Animals; Birth Weight; Body Weight; Bone and Bones; Cesarean Section; F | 1972 |
Teratological studies on thalidomide in rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Autolysis; Birth Weight; Body Weight; Bone and Bones; Cesarean | 1972 |
Chemotherapy of experimental allergic encephalomyelitis (EAE).
Topics: Allopurinol; Aminocaproates; Analgesics; Animals; Antineoplastic Agents; Azathioprine; Body Weight; | 1969 |
[Teratologic studies with imipramine in rats and rabbits. Planning and interpretation of teratologic studies under consideration of the biochemistry and toxicology of test substance].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Animals; Body Weight; Desipramine; Drug Toleranc | 1969 |
Effect of thalidomide on rat liver regeneration and diaphragm carbohydrate metabolism.
Topics: Animals; Body Weight; Diaphragm; Glucose; Glycogen; Hepatectomy; In Vitro Techniques; Liver Regenera | 1965 |